BACKGROUND: Prescription of third-generation cephalosporins and fluoroquinolones has been linked to an increasing incidence of gram-negative bacteria producing extended-spectrum beta-lactamases, methicillin-resistant Staphylococcus aureus and nosocomial infection with Clostridium difficile. Antibiotic stewardship (ABS) programmes offer evidence-based tools to control antibiotic prescription rates and thereby influence the incidence of nosocomial infection and contain the development of multidrug-resistant bacteria, but there is limited experience with such programmes at community hospitals. METHODS: We implemented an ABS programme at a 200-bed community hospital and aimed at a > 30 % reduction of cephalosporin and fluoroquinolone consumption within 1 year. Pharmacy data were obtained to estimate hospital-wide drug use density expressed in WHO-ATC-defined daily doses (DDD) or hospital-adapted recommended daily doses (RDD) per 1,000 patient days. The effect of the ABS intervention on drug use density was analysed using interrupted time-series analysis for the periods between January 2011 and March 2013 as pre-intervention, and between April 2013 and March 2014 as post-intervention period. The CDI incidence was calculated based on microbiology laboratory data. RESULTS: Cephalosporin use (measured in RDD/1,000 patient days) decreased by 33 %, and fluoroquinolone use decreased by 31 %, respectively. Interrupted time-series analysis confirmed significant changes in the drug use density trends for both cephalosporins and fluoroquinolones after the intervention as well as for total antibiotic use that decreased by 11 % while no significant effect was noted for CDI incidence rates. CONCLUSION: ABS programmes can be effective in community hospitals and may help establish ecologically advantageous antibiotic strategies when needed.
BACKGROUND: Prescription of third-generation cephalosporins and fluoroquinolones has been linked to an increasing incidence of gram-negative bacteria producing extended-spectrum beta-lactamases, methicillin-resistant Staphylococcus aureus and nosocomial infection with Clostridium difficile. Antibiotic stewardship (ABS) programmes offer evidence-based tools to control antibiotic prescription rates and thereby influence the incidence of nosocomial infection and contain the development of multidrug-resistant bacteria, but there is limited experience with such programmes at community hospitals. METHODS: We implemented an ABS programme at a 200-bed community hospital and aimed at a > 30 % reduction of cephalosporin and fluoroquinolone consumption within 1 year. Pharmacy data were obtained to estimate hospital-wide drug use density expressed in WHO-ATC-defined daily doses (DDD) or hospital-adapted recommended daily doses (RDD) per 1,000 patient days. The effect of the ABS intervention on drug use density was analysed using interrupted time-series analysis for the periods between January 2011 and March 2013 as pre-intervention, and between April 2013 and March 2014 as post-intervention period. The CDI incidence was calculated based on microbiology laboratory data. RESULTS:Cephalosporin use (measured in RDD/1,000 patient days) decreased by 33 %, and fluoroquinolone use decreased by 31 %, respectively. Interrupted time-series analysis confirmed significant changes in the drug use density trends for both cephalosporins and fluoroquinolones after the intervention as well as for total antibiotic use that decreased by 11 % while no significant effect was noted for CDI incidence rates. CONCLUSION:ABS programmes can be effective in community hospitals and may help establish ecologically advantageous antibiotic strategies when needed.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Klaus Kaier; Christian Hagist; Uwe Frank; Andreas Conrad; Elisabeth Meyer Journal: Infect Control Hosp Epidemiol Date: 2009-04 Impact factor: 3.254
Authors: George Petrikkos; Antonios Markogiannakis; Joseph Papaparaskevas; Joseph Papapareskevas; George L Daikos; George Stefanakos; Nicholas P Zissis; Athina Avlamis Journal: Int J Antimicrob Agents Date: 2007-01 Impact factor: 5.283
Authors: Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335
Authors: David M Livermore; Russell Hope; Rosy Reynolds; Ruth Blackburn; Alan P Johnson; Neil Woodford Journal: J Antimicrob Chemother Date: 2013-06-13 Impact factor: 5.790
Authors: Peter Davey; Erwin Brown; Esmita Charani; Lynda Fenelon; Ian M Gould; Alison Holmes; Craig R Ramsay; Philip J Wiffen; Mark Wilcox Journal: Cochrane Database Syst Rev Date: 2013-04-30
Authors: Johannes P Borde; Klaus Kaier; Michaela Steib-Bauert; Werner Vach; Annette Geibel-Zehender; Hansjörg Busch; Hartmut Bertz; Martin Hug; Katja de With; Winfried V Kern Journal: BMC Infect Dis Date: 2014-04-15 Impact factor: 3.090
Authors: Johannes P Borde; Sarah Nussbaum; Stefanie Hauser; Philip Hehn; Johannes Hübner; Gabriela Sitaru; Sebastian Köller; Bruno Schweigert; Katja deWith; Winfried V Kern; Klaus Kaier Journal: Infection Date: 2015-10-16 Impact factor: 3.553
Authors: Awad Al-Omari; Abbas Al Mutair; Saad Alhumaid; Samer Salih; Ahmed Alanazi; Hesham Albarsan; Maha Abourayan; Maha Al Subaie Journal: Antimicrob Resist Infect Control Date: 2020-06-29 Impact factor: 4.887
Authors: Katherine M Shea; Athena L V Hobbs; Theresa C Jaso; Jack D Bissett; Christopher M Cruz; Elizabeth T Douglass; Kevin W Garey Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie Journal: Cochrane Database Syst Rev Date: 2017-02-09
Authors: Katharina Kreitmeyr; Ulrich von Both; Alenka Pecar; Johannes P Borde; Rafael Mikolajczyk; Johannes Huebner Journal: Infection Date: 2017-04-10 Impact factor: 3.553
Authors: Irene K Louh; William G Greendyke; Emilia A Hermann; Karina W Davidson; Louise Falzon; David K Vawdrey; Jonathan A Shaffer; David P Calfee; E Yoko Furuya; Henry H Ting Journal: Infect Control Hosp Epidemiol Date: 2017-04 Impact factor: 3.254